Skip to main content

People in the News: Trovagene Names Elander as CSO; Curetis Hires Hilbert to Head Biz Development

Premium

Trovagene said this week that it has appointed Mark Elander as chief scientific officer. Erlander will direct the clinical development program for the company's portfolio of transrenal and urine-based molecular diagnostic assays. He will also oversee the ongoing clinical program for Trovagene's human papilloma virus carrier screening assay.

Elander previously served as CSO of BioTheranostics, a BioMérieux company. Prior to this, he was a research fellow at the RW Johnson Pharmaceutical Research Institute, part of Johnson & Johnson. He has also been a postdoctoral fellow in the Department of Molecular Biology at Scripps Research Institute. He holds a BS in biochemistry from the University of California, Davis; an MS in biochemistry from Iowa State University, and a PhD in neuroscience from the University of California, Los Angeles.


Curetis this week said that it has appointed Helmut Hilbert as head of business development.

Hilbert was previously employed by Qiagen, where he served in a number of scientific and business development positions, most recently associate director of corporate business development. He holds a PhD in molecular biology from the Open University/University of Heidelberg.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.